Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma.
| Autor: | Hernandez BY; Authors' Affiliations: University of Hawaii Cancer Center; The Queen's Medical Center; University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii; Division of Cancer Epidemiology and Genetics, and Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland., Zhu X, Kwee S, Chan OT, Tsai N, Okimoto G, Horio D, McGlynn KA, Altekruse S, Wong LL |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2013 Nov; Vol. 22 (11), pp. 2016-23. Date of Electronic Publication: 2013 Aug 27. |
| DOI: | 10.1158/1055-9965.EPI-13-0397 |
| Abstrakt: | Background: Hepatocellular carcinoma (HCC) incidence is increasing in the United States. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are major causes of HCC. Hepatitis infection in patients with HCC is generally diagnosed by serology, which is not always consistent with the presence of HBV and HCV in the liver. The relationship of liver viral status to serostatus in hepatocarcinogenesis is not fully understood. Methods: HBV and HCV were evaluated in formalin-fixed, paraffin-embedded liver tissue specimens in a retrospective study of 61 U.S. HCC cases of known serologic status. HBV DNA and HCV RNA were detected by PCR, reverse transcription PCR (RT-PCR), and pyrosequencing, and HBsAg and HBcAg were evaluated by immunohistochemistry. Results: Viral markers were detected in the liver tissue of 25 of 61 (41%) HCC cases. Tissue viral and serologic status were discordant in 27 (44%) cases, including those with apparent "occult" infection. Specifically, HBV DNA was detected in tissue of 4 of 39 (10%) serum HBsAg (-) cases, including 1 anti-HCV(+) case; and HCV RNA was detected in tissue of 3 of 42 (7%) anti-HCV seronegative cases, including two with serologic evidence of HBV. Conclusions: Viral hepatitis, including HBV-HCV coinfection, may be unrecognized in up to 17% of patients with HCC when based on serology alone. Further research is needed to understand the clinical significance of viral makers in liver tissue of patients with HCC in the absence of serologic indices. Impact: The contribution of HBV and HCV to the increasing incidence of HCC in the United States may be underestimated. (©2013 AACR.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|